Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06799494 · ClinicalTrials.gov registry record · Phase 4
HPV Vaccine Reduced Dose
A Phase 4 study of Hpv, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06799494 is a Phase 4 study of Hpv that is actively recruiting participants, run by Emory University. The registered enrollment target is 100 participants, below the 2,237-participant average among 24 other Hpv trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06799494, a Phase 4 study of Hpv, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to answer the question: does 1-dose HPV vaccination generate the same immune responses compared to 2- or 3-dose HPV vaccination? This will be done by studying the immune response in blood, lymph nodes, and bone marrow. Human papillomaviruses (HPV) cause cancers (cervical, anal, oropharyngeal, vulvar, vaginal, and penile), and the current HPV vaccine is highly effective at preventing disease by HPV types that cause 90% of cancer cases. While this vaccine generates high levels of antibodies that last for \> 10 years, understanding of how this occurs is limited, and studying this immune response will help design new and better vaccines. The study population consists of healthy adult (age 18-45) participants who have not previously received an HPV vaccine, do not have antibodies against certain types of HPV, do not have a history of HPV infection or disease (such as genital warts, abnormal pap test, or HPV DNA test), and do not have contraindications to study procedures. Populations of increased concern are not being enrolled.
Conditions Studied
Interventions
- DRUG Lorazepam
- BIOLOGICAL Gardasil-9
- DRUG Lidocaine injection
Study Locations (1)
Georgia
- Hope Clinic of the Emory Vaccine Center - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-08-06 |
| Est. Completion | 2028-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06799494
The ClinicalTrials.gov registry entry for NCT06799494 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,237-participant average among 24 other Hpv trials with a reported enrollment target (96% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hpv appearing as the primary indexed condition, and to 3 interventions - of which Lorazepam is the first listed.
NCT06799494 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06799494 about?
NCT06799494 is a clinical study titled "HPV Vaccine Reduced Dose". This study aims to answer the question: does 1-dose HPV vaccination generate the same immune responses compared to 2- or 3-dose HPV vaccination? This will be done by studying the immune response in blood, lymph nodes, and bone marrow. Human papillomaviruses (HPV) cause cancers (cervical, anal, orop...
What is the current status of trial NCT06799494?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2025-08-06. Estimated completion is 2028-09.
What conditions does trial NCT06799494 study?
This clinical trial studies the following conditions: Hpv.
What interventions are being tested in trial NCT06799494?
The interventions under investigation include: Lorazepam (DRUG), Gardasil-9 (BIOLOGICAL), Lidocaine injection (DRUG).
Who is sponsoring clinical trial NCT06799494?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06799494 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hpv
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessing Durable Antibody Response to HPV Vaccination
ACTIVE NOT RECRUITING · Phase 4
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination
RECRUITING · NA
-
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
RECRUITING · Phase 2
-
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
RECRUITING
-
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.